Preview

Научно-практическая ревматология

Расширенный поиск

Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний

https://doi.org/10.14412/1995-4484-2013-1547

Полный текст:

Аннотация

В настоящее время достигнуты значительные успехи в лечении иммуновоспалительных ревматических заболеваний, связанные с расшифровкой фундаментальных патогенетических механизмов их развития. Наиболее хорошо изученными терапевтическими «мишенями» являются фактор некроза опухоли α, интерлейкин 6 (ИЛ6) и ИЛ1, однако ингибиция этих цитокинов с использованием генно-инженерных биологических препаратов не всегда клинически эффективна и редко приводит к развитию ремиссии. Новое перспективное направление в лечении ревматоидного артрита (РА) и других воспалительных артритов связывают с ингибицией ИЛ17А, провоспалительного цитокина, участвующего в развитии воспаления и деструкции костной ткани. В статье суммированы новые данные, касающиеся перспектив применения моноклональных антител к ИЛ17 для лечения РА.

Об авторах

Евгений Львович Насонов
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва
Россия


L N Denisov
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва
Россия


M L Stanislav
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва
Россия


Список литературы

1. <div><p>Насонов ЕЛ. Современные направления иммунологических исследований при хронических воспалительных и аутоиммунных заболеваниях человека. Терапевтический архив. 2001;(8):43–6. [Nasonov EL. Sovremennye napravleniya immunologicheskikh issledovaniy pri khronicheskikh vospalitel'nykh i autoimmunnykh zabolevaniyakh cheloveka. Terapevticheskiy arkhiv. 2001;(8):43–6.]</p><p>Насонов ЕЛ. Перспективы лечения ревматических заболеваний в начале 21 века. Терапевтический Архив. 2011;(5):5–9. [Nasonov EL. Perspektivy lecheniya revmaticheskikh zabolevaniy v nachale 21 veka. Terapevticheskiy Arkhiv. 2011;(5):5–9.]</p><p>Генно-инженерные биологические биологические препараты в лечении ревматоидного артрита. Под редакцией Насонова ЕЛ. Москва: ИМА-ПРЕСС; 2013. С. 549. [Genno-inzhenernye biologicheskie biologicheskie preparaty v lechenii revmatoidnogo artrita. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 549.]</p><p>Pope J, Combe B. Unmet needs in the treatment of rheumatoid arthritis. J Rheumatol Autoimmue Dis. 2013;3:65–78. DOI: http://dx.doi.org/10.4236%2Fojra.2013.32011.</p><p>Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73. DOI: http://dx.doi.org/10.1146%2Fannurev.iy.07.040189.001045.</p><p>Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci. 2012;122(11):487–511. DOI: http://dx.doi.org/10.1042%2FCS20110496.</p><p>Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311–21. DOI: http://dx.doi.org/10.1111%2Fj.1365-2567.2009.03240.x.</p><p>Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009;11(5):625–30. DOI: http://dx.doi.org/10.1016%2Fj.micinf.2009.04.003.</p><p>Qu N, Xu M, Mizoguchi I et al. Oivotal roles of T-helper 17-telated cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Devel Immunol. 2013; ID 968549l.</p><p>Martin DA, Towne JE, Kricorian G et al. The emerging role of IL-17 in the pathogeneasis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26. DOI: http://dx.doi.org/10.1038%2Fjid.2012.194.</p><p>Qian Y, Kang Z, Liu C, Li X. IL-17 signaling in host defense and inflammatory diseases. Cell Mol Immunol. 2010;7(5):328–33. http://dx.doi.org/10.1038%2Fcmi.2010.27.</p><p>Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9(8):556–67. DOI: http://dx.doi.org/10.1038%2Fnri2586</p><p>Kimura A, Kishimoto T. IL 6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. DOI: http://dx.doi.org/10.1002%2Feji.201040391.</p><p>Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskeletal Dis. 2013;5(3):141–52. DOI: http://dx.doi.org/10.1177%2F1759720X13485328.</p><p>Gaffen S. Role of IL-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep. 2009;11:365–70.</p><p>Sarkar S, Cooney LA, Fox DA. The role of T helper type 17 cells in inflammatory arthritis. Clin Exp Immunol. 2009;159(3):225–37. DOI: http://dx.doi.org/10.1111%2Fj.1365-2249.2009.04016.x.</p><p>Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. J Inflam Res. 2010;3:33–44. DOI: http://dx.doi.org/10.2147%2FJIR.S6375</p><p>Lubbers E. Th17 cytokines and arthritis. Semin Immunopatjol. 2010;04 Feb.</p><p>Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173–7.</p><p>Plater-Zyberk C, Joosten L, Helsen M et al. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model. Ann Rheum Dis. 2009;68:721–8.</p><p>Lubberts E, Koenders M, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50(2):650–9. DOI: http://dx.doi.org/10.1002%2Fart.20001.</p><p>Bush K, Farmer K, Walker J, Kirkham B. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002;46(3):802–5. DOI: http://dx.doi.org/10.1002%2Fart.10173.</p><p>Chao C, Chen S, Adamopoulos I et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity. 2011;44(3):243–52. http://dx.doi.org/10.3109%2F08916934.2010.517815.</p><p>Koenders M, Lubberts E, Oppers-Walgreen B et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005;167(1):141–9. DOI: http://dx.doi.org/10.1016%2FS0002-9440%2810%2962961-6.</p><p>Ishiguro A, Akiyama T, Adachi H et al. Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum. 2011;63(2):455–66. DOI: http://dx.doi.org/10.1002%2Fart.30108.</p><p>Metawi S, Abbas D, Kamal M, Ibrahim M. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol. 2011;30(9):1201–7. DOI: http://dx.doi.org/10.1007%2Fs10067-011-1737-y.</p><p>Moran E, Mullan R, McCormick J et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biological therapies. Arthritis Res Ther. 2009;11(4):R113. DOI: http://dx.doi.org/10.1186%2Far2772.</p><p>Park J, Park M, Lee S, Oh H et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine. 2012;60(1):143–9. DOI: http://dx.doi.org/10.1016%2Fj.cyto.2012.06.285.</p><p>Suurmond J, Dorjee A, Boon M, et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther. 2011;13(5):R150. DOI: http://dx.doi.org/10.1186%2Far3466.</p><p>Ziolkowska M, Koc A, Luszczykiewicz G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol. 2000;164:2832–8.</p><p>Suurmond J, Dorjee A, Boon M et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther. 2011;13(5):R150. http://dx.doi.org/10.1186%2Far3466.</p><p>Chen D, Chen Y, Chen H et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2022;13(4):R126. DOI: http://dx.doi.org/10.1186%2Far3431.</p><p>Alzabin S, Abraham S, Taher T et al. Incomplete responses of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 2012;71:1741–8.</p><p>Adamopoulos I, Chao C, Geissler R et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther. 2010;12(1): R29. DOI: http://dx.doi.org/10.1186%2Far2936.</p><p>Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673–82. DOI: http://dx.doi.org/10.1084%2Fjem.20061775</p><p>Dharmapatni A, Smith M, Crotti T et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011;13(2):R51. DOI: http://dx.doi.org/10.1186%2Far3294.</p><p>Park J, Park M, Lee S et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine. 2012;60(1):143–9. DOI: http://dx.doi.org/10.1016%2Fj.cyto.2012.06.285.</p><p>Hueber A, Asquith D, Miller A et al. Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336–40. DOI: http://dx.doi.org/10.4049%2Fjimmunol.0903566.</p><p>Lin AM, Rubin CJ, Khandpup R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1);490–500. DOI: http://dx.doi.org/10.4049%2Fjimmunol.1100123.</p><p>Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol. 2012;9(6):375-9. DOI: http://dx.doi.org/10.1038%2Fnrrheum.2012.205. Epub 2012 Dec 11..</p><p>Корсакова ЮЛ, Станислав МЛ, Денисов ЛН, Насонов ЕЛ. Устекинумаб – новый препарат для лечения псориаза и псориатического артрита. Научно-практическая ревматология. 2012;2(51):170–80. [Korsakova YL, Stanislav ML, Denisov LN, Nasonov EL. Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2012;51(2):170–80.]</p><p>Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii116–23. DOI: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19.</p><p>Hueber W, Patel D, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. DOI: 10.1126/scitranslmed.3001107.</p><p>Genovese M, Durez P, Richards H et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2012;72(6):863–9. DOI: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.</p><p>Gnanasakthy A, Kosinski M, Genovese M et al. Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:666.</p><p>Strand V, Genovese M, Mallya U et al. Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: results of a dose-finding study [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:671.</p><p>Genovese M, Kellner H, Durez P et al. Secukinumab treatment improves ACR50, HAQ-DI and EULAR remission rates in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:191.</p><p>Leonardi C, Matheson R, Zacharie C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. DOI: 10.1056/NEJMoa1109997..</p><p>Genovese M, Van den Bosch F, Roberson S et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. 2010;62(4):929–39. DOI: 10.1002/art.27334.</p><p>Genovese M, Greenwald M, Cho C et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors [abstract]. Arthritis Rheum. 2011;63 Suppl 10:S1017.</p><p>Papp K, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9. DOI: 10.1056/NEJMoa1109017.</p><p>Pavelka K, Chon Y, Newmark R et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum. 2010;64 Suppl 10:S362.</p><p>Leonardi C, Matheson R, Zacharie C et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9. DOI: 10.1056/NEJMoa1109997..</p><p>Papp K, Langley R, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2012;168(2):412–21. DOI: 10.1111/bjd.12110. Epub 2013 Jan 18.</p><p>Papp K, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9. DOI: 10.1056/NEJMoa1109017.</p><p>McInnes I, Sieper J, Braun J et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial (abstract). Arthritis Rheum. 2011;63 Suppl 10:779.</p><p>U.S. National Institutes of Health. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov (accessed 30 Sep 2012).</p><p>Baeten D, Sieper J, Emery P et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of ankylosing spondylitis (abstract). Ann Rheum Dis. 2011;70 Suppl 3:127.</p><p>Baraliakos X, Braun J, Laurent DD et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging (abstract). Arthritis Rheum. 2011;63 Suppl 10:2486D.</p><p>Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310–6. DOI: http://dx.doi.org/10.1172%2FJCI21404</p><p>Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693¬700. DOI: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.</p><p>Ogawa A, Andoh A, Araki Y et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110(1):55–62. DOI: http://dx.doi.org/10.1016%2Fj.clim.2003.09.013.</p></div><br />


Для цитирования:


Насонов Е.Л., Denisov L.N., Stanislav M.L. Интерлейкин 17 – новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2013;51(5):545-552. https://doi.org/10.14412/1995-4484-2013-1547

For citation:


Nasonov E.L., Denisov L.N., Stanislav M.L. INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES. Rheumatology Science and Practice. 2013;51(5):545-552. (In Russ.) https://doi.org/10.14412/1995-4484-2013-1547

Просмотров: 1181


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)